BACHADON BO‘YNI SARATONINI ERTA TASHXISLASHDA HPV TESTI VA SITOLOGIK TEKSHIRUVNING DIAGNOSTIK SAMARADORLIGI
DOI:
https://doi.org/10.5281/zenodo.23532120Keywords:
bachadon bo‘yni saratoni, HPV DNK testi, PAP-test, suyuqlik sitologiyasi, CIN2+, sezgirlik, spetsifiklik, skriningAbstract
Maqolada bachadon bo‘yni saratoni va yuqori darajali servikal intraepitelial neoplaziyalarni (CIN2+) erta aniqlashda yuqori onkogen xavfli odam papillomavirusi (HPV) DNK testi hamda sitologik tekshiruvning diagnostik samaradorligi tahlil qilindi. Tadqiqot dizayni — milliy hujjatlar, mahalliy tadqiqotlar va xalqaro qo‘llanmalarga asoslangan narrativ-tahliliy adabiyotlar sharhi. Sezgirlik, spetsifiklik, klinik saralash (triage) va skrining intervallari qiyoslandi. HPV asosidagi birlamchi skrining yuqori sezgirlikka ega, sitologiya esa HPV-musbat ayollarni keyingi tekshiruvga saralashda muhim ahamiyatga ega. Natijalar klinik individual ma’lumotlarga emas, balki e’lon qilingan manbalar sinteziga asoslangan.References
1. O‘zbekiston Respublikasi Prezidenti. (2024). Ayollar orasida onkologik kasalliklarni nazorat qilish tizimini takomillashtirish chora-tadbirlari to‘g‘risida (PQ–402-son, 22-noyabr). https://lex.uz/docs/-7232845
2. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (Sana ko‘rsatilmagan). Bachadon bo‘yni saratoni nima? https://gov.uz/oz/ssv/sections/view/39102
3. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2026, 13-iyul). Olti turdagi saraton kasalliklari bo‘yicha tibbiy tekshiruvlar qamrovi kamida 60 foizga yetkaziladi. https://gov.uz/oz/ssv/news/view/192166
4. O‘zbekiston Respublikasi Oliy attestatsiya komissiyasi. (Sana ko‘rsatilmagan). Odam papillomavirusi va bachadon bo‘yni saratoni skriningiga oid dissertatsiya ilmiy natijalari (e’lon sahifasi). https://oak.uz/ pages/22814
5. O‘zbekiston Respublikasi Oliy attestatsiya komissiyasi. (Sana ko‘rsatilmagan). Andijon viloyati modelida bachadon bo‘yni saratonini skrining qilish bo‘yicha tadqiqot (e’lon sahifasi). https://oak.uz/pages/11440
6. O‘zbekiston Respublikasi Oliy attestatsiya komissiyasi. (Sana ko‘rsatilmagan). HPV bilan bog‘liq bachadon bo‘yni shikastlanishlarini diagnostika qilish bo‘yicha tadqiqot (e’lon sahifasi). https://www.oak.uz/index.php/ pages/23366
7. O‘zbekiston Respublikasi Oliy attestatsiya komissiyasi. (2026). Bachadon bo‘yni saratonoldi kasalliklarini o‘rganish bo‘yicha ilmiy natijalar (e’lon sahifasi). https://oak.uz/pages/32527
8. O‘zbekiston Respublikasi Oliy attestatsiya komissiyasi. (2025). Klimakterik yoshdagi ayollarda bachadon bo‘yni neoplaziyasi sitologiyasi bo‘yicha ilmiy natijalar (e’lon sahifasi). https://oak.uz/index.php/pages/28168
9. Lutfillayeva, U., Abdiyeva, M., & Bekbauliyeva, G. (2025). Bachadon bo‘yni fon kasalliklarini tashxislashning zamonaviy jihatlari. Journal of Education and Scientific Medicine. https://www.journals.tma.uz/index.php/ jesm/article/download/1195/1142
10. Yunusova, A. (2026, 19-sentabr). HPV va bachadon bo‘yni saratoni: skriningdan profilaktikagacha zamonaviy yo‘l xaritasi. Med1.uz. https://www.med1.uz/articles/ginekologiya/hpv-bachadon-boynisaratoni-skrining-profilaktika
11. World Health Organization. (2021). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention (2nd ed.). https://www.who.int/publications-detail-redirect/9789240030824
12. World Health Organization. (2021). WHO guideline for screening and treatment of cervical pre-cancer lesions: Questions and answers. https://www.who.int/news/item/06-07-2021-q-and-a-screening-andtreatment-cervical-pre-cancer-lesions-for-cervical-cancer-prevention
13. Chao, Y. S., Clark, M., Carson, E., et al. (2019). HPV testing for primary cervical cancer screening: A health technology assessment. Canadian Agency for Drugs and Technologies in Health. https://www.ncbi.nlm. nih.gov/books/NBK543096/table/ch5.tab8/
14. World Health Organization Regional Office for Europe. (2021). WHO recommends DNA testing as a firstchoice screening method for cervical cancer prevention. https://www.who.int/europe/news/item/11-09-2021-who-recommends-dna-testing-as-a-first-choice-screening-method-for-cervical-cancer-prevention
15. World Health Organization. (2021). WHO guideline for screening and treatment of cervical pre-cancer lesions: Use of mRNA tests for human papillomavirus (HPV). https://www.who.int/publications/i/ item/9789240040434
Downloads
Published
How to Cite
Issue
Section
